BioLife Solutions Stock News

Start Time: 16:30 January 1, 0000 5:02 PM ET BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2024 Earnings Conference Call May 09, 2024, 16:30 PM ET Company Participants Rod de Greef - Chairman and CEO Troy

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago.

Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38%  and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40%  to 53%  and adjusted EBI

BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an

BOTHELL, Wash. , April 18, 2024 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the c

BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an

BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript

Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and posi

BOTHELL, Wash. , Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an

Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. , Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a

BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene t

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participa

BOTHELL, Wash. , Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of $33.3 milli